Overview

EPI-743 for Mitochondrial Respiratory Chain Diseases

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of EPI-743 in participants with severe mitochondrial respiratory chain diseases who are considered to be within 90 days of end-of-life care.
Phase:
Phase 2
Details
Lead Sponsor:
Edison Pharmaceuticals Inc
PTC Therapeutics
Treatments:
Ubiquinone